Table 2.
Baseline clinical characteristics and 1q abnormalities of the patients with multiple myeloma.
| Patients’ clinical characteristics | All (N = 258) | 1q normal (n = 131) | 1q gain (n = 127) | P |
|---|---|---|---|---|
| Sex(male) n (%) | 146 (56.6) | 72 (55.0) | 74 (58.3) | 0.592 |
| Age(≤65 y), n (%) | 156 (60.5) | 85 (64.9) | 71 (55.9) | 0.140 |
| Type of M protein, n (%) | 0.413 | |||
| IgA | 63 (24.4) | 29 (22.1) | 34 (26.8) | |
| IgG | 123 (47.7) | 60 (45.8) | 63 (49.6) | |
| IgD | 15 (5.8) | 8 (6.1) | 7 (5.5) | |
| Light chain | 55 (21.3) | 32 (24.4) | 23 (18.1) | |
| Double clone | 2 | 2 (1.5) | 0 (0) | |
| Durie-Salmon staging system, n (%) |
0.009 | |||
| 1A+2A | 48 (18.6) | 34 (26.0) | 14 (11.0) | |
| 3A | 167 (64.7) | 77 (58.7) | 90 (70.9) | |
| 2B+3B | 43 (16.7) | 20 (15.3) | 23 (18.1) | |
| ISS staging system | 0.153 | |||
| 1 | 86 (33.3) | 50 (38.2) | 36 (28.3) | |
| 2 | 79 (30.6) | 34 (26.0) | 45 (35.4) | |
| 3 | 93 (36.0) | 47 (35.9) | 46 (36.1) | |
| Hb (g/L), median (range) | 95.0 (42.0–161.0) | 99.5 (51.0–161.0) | 87.0 (42.0–142.0) | 0.001 |
| platelet (×10e9/L), median (range) | 177 (23–513) | 190 (42–513) | 169.5 (23–397) | 0.032 |
| Creatine (umol/L), median (range) | 84 (33–1033) | 87 (33–945) | 82 (39–1033) | 0.864 |
| LDH (u/L), median (range) | 185 (79–5758) | 172 (79–550) | 193 (94–5758) | 0.113 |
| Percentage of bone marrow plasma cells (%) median (range) |
29.0 (3.0–99.0) | 19.5 (3.0–99.0) | 31.0 (4.5–97.0) | 0.001 |
| Calcium, median (range) | 2.25 (1.62–3.95) | 2.26 (1.78–3.95) | 2.24 (1.62–3.93) | 0.728 |
| CRP, median (range) | 2.25 (0–204.2) | 2.4 (0–204.2) | 2.0 (0–192.2) | 0.649 |
| Alb, median (range) | 38.4 (19.5–64.3) | 38.6 (19.5–53.0) | 37.8 (21.3–64.3) | 0.234 |
| β2MG, median (range) | 3.90 (1.03–40.1) | 3.64 (1.03–40.1) | 4.10 (1.08–30.61) | 0.650 |
| Extramedullary lesions, n (%) |
64 (24.8) | 34 (26.0) | 30 (23.6) | 0.665 |
| Therapy, n (%) | 0.176 | |||
| PAD | 34 (13.2) | 21 (16.0) | 13 (10.2) | |
| PCD | 159 (61.6) | 82 (62.6) | 77 (60.6) | |
| PTD | 17 (6.6) | 5 (3.8) | 12 (9.4) | |
| PD | 48 (18.6) | 23 (17.6) | 25 (19.7) | |
| ASCT, n (%) | 33 (12.8) | 18(13.7) | 15 (11.8) | 0.643 |
| Del (13q), n (%) | 111 (43.0) | 35 (26.7) | 76 (59.8) | <0.001 |
| Del (17p), n (%) | 14 (5.4) | 5 (3.8) | 9 (7.1) | 0.246 |
| IgH rearrangement, n (%) | 86 (33.3) | 25 (19.1) | 61 (48.0) | <0.001 |
| FISH abnormalities (excluding 1q), n (%) |
<0.001 | |||
| 0 | 116 (45.0) | 82 (62.6) | 34 (26.8) | |
| 1 | 82 (31.8) | 35 (26.7) | 47 (37.0) | |
| 2–3 | 60 (23.2) | 14 (10.7) | 46 (36.2) |